within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP52_DasabuvirOmbitasvirParitaprevirAndRitonavir;
model DasabuvirOmbitasvirParitaprevirAndRitonavir 
   extends Pharmacolibrary.Drugs.ATC.J.J05AP52;

  annotation(Documentation(
    info ="<html><body><p>Dasabuvir, ombitasvir, paritaprevir, and ritonavir is a fixed-dose combination regimen used as antiviral therapy for chronic hepatitis C virus (HCV) infection. Paritaprevir (an NS3/4A protease inhibitor) is boosted with ritonavir (a CYP3A inhibitor), ombitasvir is an NS5A inhibitor, and dasabuvir is a non-nucleoside NS5B polymerase inhibitor. This fixed combination (also marketed as Viekira Pak) is approved for the treatment of HCV genotype 1 and was widely used but has been largely superseded by newer regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult subjects after oral administration (fed state). Parameters are predominantly derived from population PK and single/multiple dose studies.</p><h4>References</h4><ol><li><p>Flisiak, R, &amp; Flisiak-Jackiewicz, M (2017). Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. <i>Expert review of gastroenterology &amp; hepatology</i> 11(6) 559–567. DOI:<a href=&quot;https://doi.org/10.1080/17474124.2017.1309284&quot;>10.1080/17474124.2017.1309284</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28317409/&quot;>https://pubmed.ncbi.nlm.nih.gov/28317409</a></p></li><li><p>Mensing, S, et al., &amp; Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. <i>The AAPS journal</i> 18(1) 270–280. DOI:<a href=&quot;https://doi.org/10.1208/s12248-015-9846-1&quot;>10.1208/s12248-015-9846-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26597291/&quot;>https://pubmed.ncbi.nlm.nih.gov/26597291</a></p></li><li><p>Rosenthal, P, et al., &amp; Leung, DH (2020). Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. <i>Advances in therapy</i> 37(7) 3299–3310. DOI:<a href=&quot;https://doi.org/10.1007/s12325-020-01389-9&quot;>10.1007/s12325-020-01389-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32451952/&quot;>https://pubmed.ncbi.nlm.nih.gov/32451952</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end DasabuvirOmbitasvirParitaprevirAndRitonavir;
